Cambrex Completes Highly Potent API Manufacturing Facility at Charles City, IA
April 10 2019 - 8:00AM
Cambrex Corporation (NYSE: CBM), the leading small molecule company
providing drug substance, drug product and analytical services
across the entire drug lifecycle, today announced that it had
completed the construction of a $24 million highly potent API
(HPAPI) manufacturing facility at its site in Charles City, IA. The
6,000 sq. ft. facility is currently undergoing validation and will
be ready to commence customer projects in May 2019.
The production area will operate to an
occupational exposure limit (OEL) down to 0.1µg/m3 and contain 4
reactors ranging from 200 to 1,000 gallon capacity enabling
manufacturing campaigns of batch sizes up to 300 kg. With the
completion of this new facility, the Charles City site now has the
flexibility to support all phases of development and offer all
scales of HPAPI manufacture across the full OEL band spectrum.
“Across our sites, Cambrex has a strong
reputation in the handling and supply of potent molecules, and this
investment allows us to increase the capacity we can offer our
customers,” commented John Andrews, VP, Operations & Site
Director, Cambrex Charles City. “We have seen an increased number
of molecules in the clinical pipeline being designated as potent
and highly potent, so having the flexibility within our
manufacturing network to scale up with existing customers as
projects progress, as well as accommodate new projects, is crucial
to meet those market needs.”
Cambrex’s Charles City, Iowa facility employs over 370 people
and is located on a 45-acre site. The site is part of the company’s
Drug Substance business unit and manufactures a wide range of APIs
and pharmaceutical intermediates, including highly potent molecules
and controlled substances.
About CambrexCambrex is the
leading small molecule company that provides drug substance, drug
product and analytical services across the entire drug lifecycle.
The company provides customers with an end-to-end partnership for
the research, development and manufacture of small molecule
therapeutics. With over 35 years’ experience and a growing team of
over 2,000 experts servicing global clients from sites in North
America and Europe, Cambrex is a trusted partner in branded and
generic markets for API and dosage form development and
manufacturing.
Cambrex offers a range of specialist drug
substance technologies and capabilities including biocatalysis,
continuous flow, controlled substances, solid state science,
material characterization and highly potent APIs. In addition,
Cambrex can support conventional dosage forms including oral
solids, semi-solids and liquids and has the expertise to
manufacture specialist dosage forms such as modified-release, fixed
dose combination, pediatric, bi-layer tablets, stick packs,
topicals, controlled substances, sterile and non-sterile
ointments.
For more information, please visit
www.cambrex.com
Contact:
Alex MawDirector, Marketing and CommunicationsTel: +44 7803 443
155Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Jul 2023 to Jul 2024